[ad_1]
CurveBeam says OssView works by calculating a structural fragility score (SFS), which “determines bone microstructural deterioration, a highly accurate indicator of bone fragility and fracture risk.”
The company says SFS is used when patients are scanned with high-resolution peripheral quantitative computed tomography (HR-pQCT).
In the announcement, published on September 12, CurveBeam AI cites Ego Seeman, an endocrinologist at the University of Melbourne in Australia.
“The many women in the community with osteopenia who are at risk of fracture are unlikely to be offered treatment because of the mistaken belief that finding BMD in the osteopenic area means the bone is not fragile,” says Seeman. “Even modest bone loss that produces osteopenia simultaneously destroys bone architecture, greatly weakening the bone.”
CurveBeam AI points to figures from the National Osteoporosis Foundation that show Medicare spent about $57 billion in 2018 caring for patients who suffered osteoporotic fractures.
CurveBeam plans to offer point-of-care HR-pQCT platforms after completing the FDA review process.
The company is based in Pennsylvania, has 51 employees and is aiming for an initial public offering in 2023.
Full announcement here.
[ad_2]
Leave a Reply